South San Francisco, CA, United States of America

Karthik Nagapudi

USPTO Granted Patents = 10 (Patent Applications = 12)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 7.9

ph-index = 4

Forward Citations = 52(Granted Patents)

Location History:

Simi Valley, CA (US) (2011 - 2018)
South San Francisco, CA (US) (2021 - 2024)

Company Filing History:

Hoffmann-la Roche Inc.

patents

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12410189 - Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production (2025-09-09),

2. 12221417 - Salt of omecamtiv mecarbil and process for preparing salt (2025-02-11),

3. 11958809 - Salt of omecamtiv mecarbil and process for preparing salt (2024-04-16),

4. 11780834 - Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use (2023-10-10),

5. 11591345 - Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production (2023-02-28),

6. 11472773 - Salt of omecamtiv mecarbil and process for preparing salt (2022-10-18),

7. 11028100 - Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production (2021-06-08),

8. 10954234 - Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use (2021-03-23),

9. 9988354 - Salt of omecamtiv mecarbil and process for preparing salt (2018-06-05),

10. 7951368 - Compositions of specific binding agents to hepatocyte growth factor (2011-05-31),

Title: Karthik Nagapudi: Innovator in Pharmaceutical Patents

Introduction

Karthik Nagapudi is a prominent inventor based in South San Francisco, CA (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 10 patents. His work focuses on the development of novel compounds and methods that have the potential to impact medical treatments.

Latest Patents

Among his latest patents are innovative formulations such as polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide. He has also developed crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077). Additionally, he has worked on the salt of omecamtiv mecarbil and processes for preparing this salt, which includes omecamtiv mecarbil dihydrochloride salt forms and their pharmaceutical formulations.

Career Highlights

Karthik has had a successful career, working with notable companies such as Genentech, Inc. and Cytokinetics, Inc. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Throughout his career, Karthik has collaborated with talented individuals, including Paroma Chakravarty and Sheng Cui. These partnerships have fostered innovation and have been instrumental in advancing his research projects.

Conclusion

Karthik Nagapudi is a distinguished inventor whose work in pharmaceuticals has led to numerous patents and advancements in drug development. His contributions continue to shape the future of medical treatments and highlight the importance of innovation in the industry.

This text is generated by artificial intelligence and may not be accurate.